623 related articles for article (PubMed ID: 17097848)
1. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer.
Goonetilleke KS; Siriwardena AK
Eur J Surg Oncol; 2007 Apr; 33(3):266-70. PubMed ID: 17097848
[TBL] [Abstract][Full Text] [Related]
2. Serum CA 242: the search for a valid marker of pancreatic cancer.
Ventrucci M; Ubalducci GM; Cipolla A; Panella MA; Ligabue A
Clin Chem Lab Med; 1998 Mar; 36(3):179-84. PubMed ID: 9589807
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patients.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1992; 12(6B):2309-14. PubMed ID: 1295478
[TBL] [Abstract][Full Text] [Related]
4. Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas.
Satake K; Takeuchi T
Pancreas; 1994 Nov; 9(6):720-4. PubMed ID: 7846015
[TBL] [Abstract][Full Text] [Related]
5. Serum Carbohydrate Antigen 19-9 in Differential Diagnosis of Benign and Malignant Pancreatic Cystic Neoplasms: A Meta-Analysis.
Cao S; Hu Y; Gao X; Liao Q; Zhao Y
PLoS One; 2016; 11(11):e0166406. PubMed ID: 27835676
[TBL] [Abstract][Full Text] [Related]
6. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
[TBL] [Abstract][Full Text] [Related]
8. [CA 19-9 in the differential diagnosis of pancreatic lesions].
Stintzing S; Herold C; Hahn EG; Boxberger F
Internist (Berl); 2008 Feb; 49(2):225-7. PubMed ID: 18210015
[TBL] [Abstract][Full Text] [Related]
9. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
10. Tumor markers in the diagnosis, monitoring and therapy of pancreatic cancer: state of the art.
Plebani M; Basso D; Panozzo MP; Fogar P; Del Favero G; Naccarato R
Int J Biol Markers; 1995; 10(4):189-99. PubMed ID: 8750644
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic cancer and tumor markers: role of the newly identified CAR-3 antigen.
Giulianotti PC; Boggi U; Ferdeghini M; Di Candio G; Caravaglios G; Bellini R; Mosca F
Ann Ital Chir; 1997; 68(3):307-13. PubMed ID: 9419908
[TBL] [Abstract][Full Text] [Related]
12. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9.
Ballehaninna UK; Chamberlain RS
Tumour Biol; 2013 Dec; 34(6):3279-92. PubMed ID: 23949878
[TBL] [Abstract][Full Text] [Related]
14. CA 19-9: Biochemical and Clinical Aspects.
Scarà S; Bottoni P; Scatena R
Adv Exp Med Biol; 2015; 867():247-60. PubMed ID: 26530370
[TBL] [Abstract][Full Text] [Related]
15. Systematic review on the role of serum tumor markers in the detection of recurrent pancreatic cancer.
Daamen LA; Groot VP; Heerkens HD; Intven MPW; van Santvoort HC; Molenaar IQ
HPB (Oxford); 2018 Apr; 20(4):297-304. PubMed ID: 29366815
[TBL] [Abstract][Full Text] [Related]
16. Clinical value and impact on prognosis of peri-operative CA 19-9 serum levels in stage I and II adenocarcinoma of the pancreas.
Piagnerelli R; Marrelli D; Roviello G; Ferrara F; Di Mare G; Voglino C; Petrioli R; Marini M; Macchiarelli R; Roviello F
Tumour Biol; 2016 Feb; 37(2):1959-66. PubMed ID: 26334620
[TBL] [Abstract][Full Text] [Related]
17. Serum APRIL, a potential tumor marker in pancreatic cancer.
Wang F; Chen L; Ding W; Wang G; Wu Y; Wang J; Luo L; Cong H; Wang Y; Ju S; Shao J; Wang H
Clin Chem Lab Med; 2011 Oct; 49(10):1715-9. PubMed ID: 21612541
[TBL] [Abstract][Full Text] [Related]
18. Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy.
Yang KS; Im H; Hong S; Pergolini I; Del Castillo AF; Wang R; Clardy S; Huang CH; Pille C; Ferrone S; Yang R; Castro CM; Lee H; Del Castillo CF; Weissleder R
Sci Transl Med; 2017 May; 9(391):. PubMed ID: 28539469
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic cytokines in the sera of patients with pancreatic cancer.
Mroczko B; Szmitkowski M; Wereszczyńska-Siemiatkowska U; Jurkowska G
Clin Chem Lab Med; 2005; 43(2):146-50. PubMed ID: 15843207
[TBL] [Abstract][Full Text] [Related]
20. A prospective multicenter trial evaluating diagnostic validity of multivariate analysis and individual serum marker in differential diagnosis of pancreatic cancer from benign pancreatic diseases.
Hayakawa T; Naruse S; Kitagawa M; Ishiguro H; Kondo T; Kurimoto K; Fukushima M; Takayama T; Horiguchi Y; Kuno N; Noda A; Furukawa T
Int J Pancreatol; 1999 Feb; 25(1):23-9. PubMed ID: 10211418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
